Therapeutic efficacy and safety of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye

Xiao Dong Sun, Wei Qi Xu, Philip J Rosenfeld

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Clinical trial of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye showed good therapeutic results. It has been demonstrated that this therapy is efficient and safe in the treatment of choroidal neovascularization due to age-related macular degeneration, pathologic myopia and other neovascular eye diseases in short term period. The potential risks to the patients are minimal, and the cost-effectiveness is so obvious that the treatment strategy using intravitreal bevacizumab is logical and understandable.

Original languageEnglish
Pages (from-to)281-284
Number of pages4
JournalChinese Journal of Ophthalmology
Volume44
Issue number3
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

Off-Label Use
Eye Diseases
Safety
Therapeutics
Choroidal Neovascularization
Myopia
Macular Degeneration
Cost-Benefit Analysis
Bevacizumab
Clinical Trials

Keywords

  • Angiogenesis inhibitors
  • Antibodies, monoclonal
  • Eye diseases
  • Neovascularization, pathologic

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Therapeutic efficacy and safety of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye. / Sun, Xiao Dong; Xu, Wei Qi; Rosenfeld, Philip J.

In: Chinese Journal of Ophthalmology, Vol. 44, No. 3, 01.03.2008, p. 281-284.

Research output: Contribution to journalArticle

@article{8c4a0df030674a488955d06a87d64873,
title = "Therapeutic efficacy and safety of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye",
abstract = "Clinical trial of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye showed good therapeutic results. It has been demonstrated that this therapy is efficient and safe in the treatment of choroidal neovascularization due to age-related macular degeneration, pathologic myopia and other neovascular eye diseases in short term period. The potential risks to the patients are minimal, and the cost-effectiveness is so obvious that the treatment strategy using intravitreal bevacizumab is logical and understandable.",
keywords = "Angiogenesis inhibitors, Antibodies, monoclonal, Eye diseases, Neovascularization, pathologic",
author = "Sun, {Xiao Dong} and Xu, {Wei Qi} and Rosenfeld, {Philip J}",
year = "2008",
month = "3",
day = "1",
language = "English",
volume = "44",
pages = "281--284",
journal = "Chinese Journal of Ophthalmology",
issn = "0412-4081",
publisher = "Chinese Medical Association",
number = "3",

}

TY - JOUR

T1 - Therapeutic efficacy and safety of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye

AU - Sun, Xiao Dong

AU - Xu, Wei Qi

AU - Rosenfeld, Philip J

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Clinical trial of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye showed good therapeutic results. It has been demonstrated that this therapy is efficient and safe in the treatment of choroidal neovascularization due to age-related macular degeneration, pathologic myopia and other neovascular eye diseases in short term period. The potential risks to the patients are minimal, and the cost-effectiveness is so obvious that the treatment strategy using intravitreal bevacizumab is logical and understandable.

AB - Clinical trial of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye showed good therapeutic results. It has been demonstrated that this therapy is efficient and safe in the treatment of choroidal neovascularization due to age-related macular degeneration, pathologic myopia and other neovascular eye diseases in short term period. The potential risks to the patients are minimal, and the cost-effectiveness is so obvious that the treatment strategy using intravitreal bevacizumab is logical and understandable.

KW - Angiogenesis inhibitors

KW - Antibodies, monoclonal

KW - Eye diseases

KW - Neovascularization, pathologic

UR - http://www.scopus.com/inward/record.url?scp=57649118684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649118684&partnerID=8YFLogxK

M3 - Article

C2 - 18785551

AN - SCOPUS:57649118684

VL - 44

SP - 281

EP - 284

JO - Chinese Journal of Ophthalmology

JF - Chinese Journal of Ophthalmology

SN - 0412-4081

IS - 3

ER -